Renal Cell Cancer
Since the last renal cell carcinoma (RCC) issue of Hematology/Oncology Clinics of North America in 2011, the management of this disease has changed dramatically with more than 10 different approvals by the Food and Drug Administration for this indication across treatment settings. New options now exist for some hereditary syndromes; adjuvant therapy, and most importantly, combination therapies are now the standard for front line, with new options available for patients with metastatic disease. At the time of this writing, several other new therapies are on the horizon.
Source: Hematology/Oncology Clinics of North America - Category: Cancer & Oncology Authors: Bradley A. McGregor, Toni K. Choueiri Tags: Preface Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Food and Drug Administration (FDA) | Hematology | Kidney Cancer | Renal Cell Carcinoma